Value investing rests on a simple but strong idea: buy a company for less than it's fundamentally worth. The challenge is finding those opportunities. A decent value screen helps by filtering for stocks that score well on valuation but do not sacrifice too much in terms of profitability, financial health, and growth. It is not enough to be cheap; the underlying business needs to be solid. That disciplined approach is exactly what brings a company like Zoetis Inc (NYSE:ZTS) into focus.
Valuation: The Core of the Opportunity
The most striking feature of Zoetis right now is its valuation. The stock carries a Price/Earnings ratio of 11.83, a figure that places it cheaper than nearly 89% of its peers in the Pharmaceuticals industry. To put that in perspective, the average P/E for the industry is over 40, and the S&P 500 sits near 26.5. Looking forward, the picture is similar: the Price/Forward Earnings ratio of 10.33 is well below the S&P 500 average of 21.3.
This is not just a case of a low P/E. The company also scores exceptionally well on other valuation multiples. Based on both Enterprise Value to EBITDA and Price/Free Cash Flow, Zoetis is significantly cheaper than 85% or more of its industry. For a value investor, these metrics signal that the market may be overlooking the company's true earning power. The overall ChartMill Valuation rating sits at an 8 out of 10, confirming that the stock appears genuinely undervalued, not just cheap for a reason.
Profitability and Financial Health: The Quality Check
A low valuation only matters if the business is profitable and stable. Here, Zoetis shines. Its profitability rating is a top-tier 9 out of 10, driven by exceptional returns and margins.
- Return on Equity (ROE) stands at an astonishing 81.75%, outperforming 99% of industry peers.
- Return on Invested Capital (ROIC) is 22.27%, well above the industry average of 12.38% and a clear sign that management is efficiently deploying capital.
- Profit Margin is 27.79% and Operating Margin is 38.54%, both among the highest in the sector. These margins have also been improving in recent years.
This combination of high returns and fat margins provides a crucial margin of safety. The business generates substantial cash flow, which supports a dividend yield of 1.64% that has been growing at an average rate of 20.56% per year for over a decade. The dividend payout ratio is a sustainable 33.64%.
The health rating of 6 out of 10 is more moderate. The company carries a high Debt/Equity ratio of 2.80, which is a point of concern. However, this is offset by a very strong Altman-Z score of 4.70, indicating a very low risk of bankruptcy, and a current ratio of 3.15, showing plenty of short-term liquidity. For value investors, the high debt is a risk to monitor, but the strong cash flow generation and overall solvency metrics provide reassurance.
Growth: A Supporting Factor
Zoetis is not a high-growth story, but it offers steady, predictable expansion. Earnings Per Share have grown by 7.48% in the last year and 10.77% on average over the past several years. Revenue has grown by 7.24% annually over the same period. Analysts expect this to continue, with EPS growth of about 8.16% per year going forward.
The growth rating of 4 out of 10 reflects a modest deceleration in both revenue and EPS growth rates. For a value investor, this is acceptable. The company is not relying on explosive, high-risk growth to justify its valuation. Instead, it combines a cheap price with a proven, profitable business that is still expanding at a reasonable clip. You can review the full breakdown of these metrics in the complete fundamental analysis report for ZTS.
Putting It All Together
Zoetis presents a textbook case for value investing. It offers a strong combination of a low valuation, best-in-class profitability, and steady, if not spectacular, growth. The main caveat is the elevated debt level, but the company's cash flow and overall financial health appear more than adequate to manage it.
When a stock can check those boxes—cheap, profitable, and growing—it becomes a candidate for deeper research. For investors looking to identify similar opportunities, the screener used to find Zoetis is a good starting point. To explore more stocks that balance strong value with decent fundamentals, you can find the latest results from the decent value screen by following this link.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Zoetis Inc (NYSE:ZTS): A Top Value Stock with Undervalued Strength
Value investing rests on a simple but strong idea: buy a company for less than it's fundamentally worth. The challenge is finding those opportunities. A decent value screen helps by filtering for stocks that score well on valuation but do not sacrifice too much in terms of profitability, financial health, and growth. It is not enough to be cheap; the underlying business needs to be solid. That disciplined approach is exactly what brings a company like Zoetis Inc (NYSE:ZTS) into focus.
Valuation: The Core of the Opportunity
The most striking feature of Zoetis right now is its valuation. The stock carries a Price/Earnings ratio of 11.83, a figure that places it cheaper than nearly 89% of its peers in the Pharmaceuticals industry. To put that in perspective, the average P/E for the industry is over 40, and the S&P 500 sits near 26.5. Looking forward, the picture is similar: the Price/Forward Earnings ratio of 10.33 is well below the S&P 500 average of 21.3.
This is not just a case of a low P/E. The company also scores exceptionally well on other valuation multiples. Based on both Enterprise Value to EBITDA and Price/Free Cash Flow, Zoetis is significantly cheaper than 85% or more of its industry. For a value investor, these metrics signal that the market may be overlooking the company's true earning power. The overall ChartMill Valuation rating sits at an 8 out of 10, confirming that the stock appears genuinely undervalued, not just cheap for a reason.
Profitability and Financial Health: The Quality Check
A low valuation only matters if the business is profitable and stable. Here, Zoetis shines. Its profitability rating is a top-tier 9 out of 10, driven by exceptional returns and margins.
This combination of high returns and fat margins provides a crucial margin of safety. The business generates substantial cash flow, which supports a dividend yield of 1.64% that has been growing at an average rate of 20.56% per year for over a decade. The dividend payout ratio is a sustainable 33.64%.
The health rating of 6 out of 10 is more moderate. The company carries a high Debt/Equity ratio of 2.80, which is a point of concern. However, this is offset by a very strong Altman-Z score of 4.70, indicating a very low risk of bankruptcy, and a current ratio of 3.15, showing plenty of short-term liquidity. For value investors, the high debt is a risk to monitor, but the strong cash flow generation and overall solvency metrics provide reassurance.
Growth: A Supporting Factor
Zoetis is not a high-growth story, but it offers steady, predictable expansion. Earnings Per Share have grown by 7.48% in the last year and 10.77% on average over the past several years. Revenue has grown by 7.24% annually over the same period. Analysts expect this to continue, with EPS growth of about 8.16% per year going forward.
The growth rating of 4 out of 10 reflects a modest deceleration in both revenue and EPS growth rates. For a value investor, this is acceptable. The company is not relying on explosive, high-risk growth to justify its valuation. Instead, it combines a cheap price with a proven, profitable business that is still expanding at a reasonable clip. You can review the full breakdown of these metrics in the complete fundamental analysis report for ZTS.
Putting It All Together
Zoetis presents a textbook case for value investing. It offers a strong combination of a low valuation, best-in-class profitability, and steady, if not spectacular, growth. The main caveat is the elevated debt level, but the company's cash flow and overall financial health appear more than adequate to manage it.
When a stock can check those boxes—cheap, profitable, and growing—it becomes a candidate for deeper research. For investors looking to identify similar opportunities, the screener used to find Zoetis is a good starting point. To explore more stocks that balance strong value with decent fundamentals, you can find the latest results from the decent value screen by following this link.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.
Read full article here »